Cybersecurity firm Blue Coat Systems has decided to opt-out of an initial public offering and sell itself to software security leader Symantec for $4.65 billion.
Category: Litigation
“All Prior Art” algorithm won’t stop bad patents or actors
Stopping new inventions dead in their tracks by making them “automatically” unpatentable might sound like a good idea to some. However, programming a computer to
Contrarian patent investors see opportunity where others see risk
The emergence of contrarian patent investors – bargain hunters hoping to cash in on decidedly soft market for licensing and sales – are an indication that the
Financial patent summit to focus on IP and cybersecurity, July 20-21
Fintech, or financial technology, is a rapidly growing industry with more than $15 billion of venture capital invested to date and even more on the
PIPCO stocks soar in a surprising first half for the second quarter
In what some patent holders are hoping will be a harbinger of things to come, publicly traded IP licensing companies are enjoying an unusually strong
“Building an Innovation Economy” is focus of latest Hoover IP² event
IP², an initiative of the Hoover Institution at Stanford University, last week hosted a more than 60 IP scholars, economists and practitioners to hear and challenge research
Media use of patent “troll” is unfair says professor in Stanford Technology Law Review
The use of inaccurate, prejudicial language by newspapers, business publications and technology magazines to describe patent licensing activity biases readers and courts. That is among
Patent licensing index significantly outperformed the S&P 500 in Q1
The eagerly sought bottom for publicly traded patent licensing companies may have been reached according to the data provided by an intellectual property index that
Samsung is the leading US patent holder, 24,000 ahead of IBM
Of the top eleven active US patent holders, only four are American companies. But who gets the best return on their innovation rights is less
The impact of higher patent licensing hurdles may not be fully understood
Most patent holders would agree that licensing patents for revenue has gone from bad to awful — from difficult less than a decade ago, to
Jury awards Merck $200M in patent damages, 10% of what it had sought
A California jury has awarded pharmaceutical drug company Merck $200 million, a fraction of what it had sought, for infringement of two of its patents
Validated Merck patents could mean a $3B+ windfall, after appeals
While many high-tech patents are suffering from devaluation the value of some pharmaceutical patents is soaring. Merck & Co. won a legal victory over
ipcloseup.com 